Using genetic testing to personalize heart treatment for patients undergoing stent procedures in Qatar
| ISRCTN | ISRCTN15110009 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15110009 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsor | Qatar Precision Health Institute |
| Funders | Qatar Precision Health Institute, Hamad Medical Corporation (HMC) |
- Submission date
- 01/05/2025
- Registration date
- 07/05/2025
- Last edited
- 06/05/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Ongoing
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Pharmacogenetics has shown that certain gene variants can significantly alter the effectiveness and safety of drugs such as clopidogrel, a widely used antiplatelet agent prescribed after percutaneous coronary intervention (PCI). Despite growing global evidence supporting the clinical value of pharmacogenetic testing, its routine integration into standard clinical practice in Qatar has not yet been achieved. This study aims to implement a pharmacogenetic-guided approach to personalize clopidogrel therapy in patients undergoing PCI and requiring dual antiplatelet therapy for 12 months. Specifically, it evaluates the use of a point-of-care (POC) genotyping device to detect CYP2C19 genetic variants that are known to influence clopidogrel metabolism. Based on the test results, treating physicians may modify the antiplatelet regimen according to evidence-based guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG).
Who can participate?
Patients aged over 18 years undergoing PCI at the Catheterization Laboratory, Heart Hospital, Hamad Medical Corporation, who are clinically indicated to receive dual antiplatelet therapy.
What does the study involve?
Participation involves a one-time genetic test using a rapid POC CYP2C19 assay (via a finger-prick blood sample) and clinical follow-up over a 12-month period. During this time, the study team will collect data on clinical outcomes, including cardiovascular events, medication adjustments, and any adverse effects.
What are the possible benefits and risks of participating?
The anticipated benefit is the potential for improved treatment effectiveness and reduced adverse drug reactions through personalized therapy. The genetic test poses no known physical risk, and all procedures follow international standards for ethical conduct and data protection. Participants will be provided with contact details for study coordinators to address any questions or concerns and will be assured of the confidentiality and secure handling of their personal and medical data.
Where is the study run from?
Qatar Precision Health Institute (QPHI)
When is the study starting and how long is it expected to run for?
October 2022 to February 2026
Who is funding the study?
It is funded by the Qatar Precision Health Institute (QPHI) in collaboration with Hamad Medical Corporation (HMC)
Who is the main contact?
Dr Rania Abdel-latif, rabdellatif@qf.org.qa
Contact information
Public, Scientific, Principal investigator
Qatar Genome
Qatar Precision Health Institute
Doha
5825
Qatar
| Phone | +974 (0)70001383 |
|---|---|
| rabdellatif@qf.org.qa |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective interventional study |
| Secondary study design | Non randomised study |
| Study type | Participant information sheet |
| Scientific title | Personalization of clopidogrel antiplatelet therapy in patients undergoing percutaneous coronary intervention in Qatar |
| Study objectives | The current project aims to provide a clinical implementation of personalized therapy for cardiovascular agents (clopidogrel) via the adoption of point-of-care pharmacogenomics (POC PGX) reactive testing to guide clopidogrel therapy. Primary objectives: 1. The purpose of the study is to implement reactive PGx-testing in personalizing therapy of clopidogrel in patients with acute coronary syndrome (ACS)/coronary heart disease (CHD) via adopting POC PGx reactive testing for CYP2C19 variants 2. Assessing the clinical utility of pharmacogenomics-guided clopidogrel treatment in patients undergoing percutaneous coronary intervention (PCI) compared with the conventional non-pharmacogenetic-guided clopidogrel treatment in terms of enhancing patient outcome. Secondary objectives: 1. Evaluating the cost-effectiveness of pharmacogenomic-guided antiplatelet treatment in Qatar 2. Investigate whether patients with CYP2C19 LOF alleles would benefit from alternative antiplatelet therapy (prasugrel and ticagrelor) or from manipulating clopidogrel dosing |
| Ethics approval(s) |
1. Approved 30/10/2023, Medical Research Center- Hamad Medical Coorporation (Hamad Medical City - Hamad Medical Corporation, Doha, 3050, Qatar; +974 (0)70001383; rabdellatif@qf.org.qa), ref: None 2. Approved 19/10/2022, Institutional Review Board - Hamad Medical Corporation (Hamad Medical City - Hamad Medical Corporation, Doha, 3050, Qatar; +974 (0)40256410; irb@hamad.qa), ref: None |
| Health condition(s) or problem(s) studied | Coronary artery disease |
| Intervention | The prospective observation trial included all patients undergoing PCI and requiring dual antiplatelet therapy for 12 months. The prospective genotype-guided strategy (intervention group) will be compared against a retrospective nontailored strategy (control group), which will be 1000 patients from 01/01/2017 to 01/10/2020. The patients in the intervention group will be recruited prospectively in the catherization lab at the heart hospital, HMC. Immediately after ACS diagnosis, eligible patients will be recruited into the study after signing written informed consent. At the time of admission, the genetic test will be performed as soon as possible, and the result will be reported within 24 h. Patients identified as carriers of at least one CYP2C19 LOF allele are considered to have an at-risk genotype and will receive ticagrelor as an alternative antiplatelet therapy. Non-carriers will continue with standard clopidogrel dosing as per the invasive cardiologist. |
| Intervention type | Genetic |
| Primary outcome measure(s) |
1. Cardiovascular death: death from any cardiovascular cause or death not clearly attributable to a non-cardiovascular cause assessed using medical records within 1 year |
| Key secondary outcome measure(s) |
1. Rehospitalization and length of stay in the hospital recorded in electronic medical records (EMR) within 1 year |
| Completion date | 01/02/2026 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 80 Years |
| Sex | All |
| Target sample size at registration | 600 |
| Key inclusion criteria | 1. Patients older than 18 years 2. Written consent from the patient or legally acceptable representative (LAR) 3. Indication for PCI 4. Require an antiplatelet therapy |
| Key exclusion criteria | 1. Major bleeding 2. Contraindication to the use of antiplatelet therapy 3. Pregnant females 4. Participating in other clinical trials on a medicinal product or blood donation for less than 3 months 5. Liver cirrhosis 6. Bone marrow transplantation 7. Advanced malignancy 9. Severe thrombocytopenia |
| Date of first enrolment | 01/02/2023 |
| Date of final enrolment | 30/05/2025 |
Locations
Countries of recruitment
- Qatar
Study participating centre
Doha
3050
Qatar
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Stored in non-publicly available repository |
| IPD sharing plan | The dataset generated during and/or analysed during the current study will be stored in a non-publicly available repository |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
06/05/2025: Study's existence confirmed by Institutional Review Board - Hamad Medical Corporation.
